Levoketoconazole improves clinical signs and symptoms and patient-reported outcomes in patients with Cushing’s syndrome

PURPOSE: The efficacy of levoketoconazole in treating hypercortisolism was demonstrated in an open-label phase 3 study (SONICS) of adults with endogenous Cushing’s syndrome (CS) and baseline mean urinary free cortisol (mUFC) ≥  1.5× ULN. Clinical signs and symptoms and patient-reported outcomes from...

Descripción completa

Detalles Bibliográficos
Autores principales: Geer, Eliza B., Salvatori, Roberto, Elenkova, Atanaska, Fleseriu, Maria, Pivonello, Rosario, Witek, Przemyslaw, Feelders, Richard A., Bex, Marie, Borresen, Stina W., Puglisi, Soraya, Biller, Beverly M. K., Cohen, Fredric, Pecori Giraldi, Francesca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7864823/
https://www.ncbi.nlm.nih.gov/pubmed/33216275
http://dx.doi.org/10.1007/s11102-020-01103-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7864823/
https://www.ncbi.nlm.nih.gov/pubmed/33216275
http://dx.doi.org/10.1007/s11102-020-01103-6

Ejemplares similares